Detalhe da pesquisa
1.
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses.
Cell
; 162(5): 974-86, 2015 Aug 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-26317466
2.
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses.
Cell
; 169(2): 361, 2017 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28388418
3.
Cycling cancer persister cells arise from lineages with distinct programs.
Nature
; 596(7873): 576-582, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34381210
4.
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses.
Cell
; 164(5): 1073, 2016 Feb 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-27064190
5.
Integrative transcriptomics and cell systems analyses reveal protective pathways controlled by Igfbp-3 in anthracycline-induced cardiotoxicity.
FASEB J
; 37(6): e22977, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37219486
6.
Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE).
Breast Cancer Res
; 25(1): 2, 2023 01 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36631725
7.
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.
N Engl J Med
; 382(6): 514-524, 2020 02 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31826360
8.
Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib.
Oncologist
; 27(10): 811-821, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35917168
9.
Role for polo-like kinase 4 in mediation of cytokinesis.
Proc Natl Acad Sci U S A
; 116(23): 11309-11318, 2019 06 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31097597
10.
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.
N Engl J Med
; 379(20): 1926-1936, 2018 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30345905
11.
Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition.
Gynecol Oncol
; 160(2): 539-546, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33229045
12.
Frontiers in HER2-positive breast cancer in 2020.
Curr Opin Obstet Gynecol
; 33(1): 48-52, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33369581
13.
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
Breast Cancer Res
; 22(1): 89, 2020 08 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-32795346
14.
Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials.
Breast Cancer Res Treat
; 184(1): 23-35, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-32783178
15.
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18).
Breast Cancer Res Treat
; 183(2): 419-428, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32683565
16.
Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
Breast J
; 26(3): 368-375, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31448513
17.
Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial.
Br J Cancer
; 121(4): 318-324, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31303643
18.
Palbociclib and Letrozole in Advanced Breast Cancer.
N Engl J Med
; 375(20): 1925-1936, 2016 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-27959613
19.
Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer.
Breast Cancer Res Treat
; 175(3): 617-625, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30868391
20.
Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.
Mol Cancer
; 22(1): 175, 2023 Oct 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37915024